Efficacy of a topical formulation containing eprinomectin, esafoxolaner and praziquantel (NexGard® Combo) in the treatment of natural respiratory capillariosis of cats

Open Access

Table 2

Clinical signs and clinical scores of cats from G1 and G2 at each time point.

Clinical sign	Group	Study day
Clinical sign	Group	0 n/tot	28 (±2) n/tot	42 (±2) n/tot	70 (±2) n/tot	84 (±2) n/tot
General respiratory distress	1	2/23	0/23	0/23	–	–
General respiratory distress	2	2/17	2/17	2/17	0/17	0/17
Sneezing	1	2/23	1/23	0/23	–	–
Sneezing	2	4/17	4/17	4/17	1/17	0/17
Wheezing	1	0/23	0/23	0/23	–	–
Wheezing	2	0/17	0/17	1/17	0/17	0/17
Cough	1	7/23	2/23	0/23	–	–
Cough	2	5/17	6/17	6/17	0/17	0/17
Food intake – reduction	1	4/23	1/23	1/23	–	–
Food intake – reduction	2	3/17	4/17	4/17	1/17	0/17
Mild to moderate lethargy	1	2/23	1/23	0/23	–	–
Mild to moderate lethargy	2	3/17	2/17	3/17	2/17	1/17
Temperature	1	1/23	0/23	0/23	–	–
Temperature	2	0/17	0/17	0/17	0/17	0/17
Pale mucous membranes	1	2/23	1/23	0/23	–	–
Pale mucous membranes	2	1/17	1/17	0/17	0/17	0/17
Ocular-nasal discharge	1	3/23	2/23	1/23	–	–
Ocular-nasal discharge	2	3/17	6/17	7/17	4/17	3/17
Respiratory rate	1	2/23	1/23	1/23	–	–
Respiratory rate	2	5/17	3/17	2/17	1/17	0/17
Respiratory movements	1	1/23	1/23	1/23	–	–
Respiratory movements	2	2/17	2/17	2/17	0/17	0/17
Auscultation	1	11/23	2/23	1/23	–	–
Auscultation	2	7/17	7/17	7/17	4/17	1/17
No. of symptomatic cats	1	14/23	7/23	4/23	–	–
No. of symptomatic cats	2	12/17	14/17	14/17	10/17	4/17
Average total clinical score	1	1.4	0.5	0.2	–	–
Average total clinical score	2	1.9	1.9	1.9	0.7	0.2

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.